Furthermore, tumor-expressed GM-CSF stimulates CD45+EPC differentiation into erythroid differentiated myeloid cells (EDMCs) with an immunosuppressive phenotype, which reduces immune checkpoint therapy efficacy [11]. Here, CSF2 is linked to neoplasm.